Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Bought by Eventide Asset Management LLC

Eventide Asset Management LLC raised its holdings in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) by 5.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,134,436 shares of the company’s stock after acquiring an additional 198,216 shares during the period. Eventide Asset Management LLC owned approximately 0.06% of Inozyme Pharma worth $21,623,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Values First Advisors Inc. purchased a new stake in shares of Inozyme Pharma during the 2nd quarter worth about $76,000. Samlyn Capital LLC raised its position in shares of Inozyme Pharma by 15.0% in the 2nd quarter. Samlyn Capital LLC now owns 3,350,535 shares of the company’s stock valued at $14,943,000 after acquiring an additional 437,622 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Inozyme Pharma by 14.4% during the second quarter. The Manufacturers Life Insurance Company now owns 21,427 shares of the company’s stock worth $96,000 after acquiring an additional 2,690 shares in the last quarter. Affinity Asset Advisors LLC boosted its stake in shares of Inozyme Pharma by 8.1% during the 2nd quarter. Affinity Asset Advisors LLC now owns 2,856,252 shares of the company’s stock worth $12,739,000 after buying an additional 213,733 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Inozyme Pharma by 117.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 380,064 shares of the company’s stock valued at $1,695,000 after purchasing an additional 205,417 shares during the last quarter. Institutional investors own 88.30% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on INZY. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Inozyme Pharma in a report on Wednesday, November 6th. Wedbush reissued an “outperform” rating and set a $12.00 price target (down from $15.00) on shares of Inozyme Pharma in a research note on Tuesday, November 5th. Stifel Nicolaus initiated coverage on shares of Inozyme Pharma in a report on Thursday, September 12th. They issued a “buy” rating and a $16.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $17.00 target price (up previously from $16.00) on shares of Inozyme Pharma in a report on Tuesday, August 13th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $15.71.

Inozyme Pharma Trading Up 2.6 %

Shares of INZY stock opened at $2.72 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68. The firm has a fifty day moving average of $4.41 and a 200-day moving average of $4.77. Inozyme Pharma, Inc. has a 12-month low of $2.56 and a 12-month high of $7.80.

Inozyme Pharma (NASDAQ:INZY) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.05. On average, analysts predict that Inozyme Pharma, Inc. will post -1.59 EPS for the current fiscal year.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.